anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
PROBLEM TO BE SOLVED: To obtain the subject adhesive capable of firmly bonding a tray made of a metal to an alginate impression material by including water and/or an organic solvent, an alkaline earth metallic hydroxide and/or its salt in a specific proportion therein. SOLUTION: This adhesive for a metal to an alginate impression material is obtained by compounding (A) 100 pts.wt. of water and/or an organic solvent (e.g. ethanol) with (B) 0.1-30 pts.wt. of an alkaline earth metallic hydroxide and/or its salt (e.g. anhydrous magnesium chloride) and, as necessary, (C) a surfactant. The component B may be a state thereof dissolved or dispersed in the component A. The adhesive is used by applying thereof to a tray made of a metal with a brush, a spatula, a paint-brush, etc., or spraying thereof and naturally drying the adhesive or hot-air drying the adhesive, then piling up the alginate impression material on the tray, collecting the impression and removing the tray integral with the cured alginate impression material after hardening the alginate impression material from teeth.
PURPOSE:To provide the titled agent containing hot-water extract of oyster meat as an active component, effective to increase the lithium concentration in cerebral tissue without causing hepatic disorder, and useful as a preventive and remedy for mental disorder to which lithium is effective. CONSTITUTION:The objective agent for increasing lithium concentration can be prepared by using the hot-water extract of oyster meat, or preferably the precipitate obtained by the alcohol fractionation of the extract, as an active component. The extraction is carried out preferably at 70-80 deg.C for 2-3hr. The alcohol using in the alcohol fractionation is preferably ethanol. The agent of the present invention has extremely high safety in contrast with lithium carbonate used as conventional lithium-increasing agent which is liable to cause the hepatic disorder. Since the agent increases the lithium concentration in the cerebral tissue, it is useful as a preventive and remedy for mental disorder such as manic-depressive psychosis.
OBJECTIVE: Cardiac cephalalgia, once seen as a rare symptom of coronary artery disease, is now more recognized. It often comes with chest discomfort and autonomic dysfunction, worsened by physical activity. However, not all cases have chest symptoms or are activity induced. This report presents a case of cardiac cephalalgia and reviews 46 previous cases.
METHOD: We discuss a unique case where a patient had headache attacks without chest symptoms, autonomic dysfunction, or triggers. We reviewed English case reports of cardiac cephalalgia from 1982 to 2022 using PubMed ( http://www.ncbi.nlm.nih.gov/pubmed ).
RESULTS: A 69-year-old man presented with a sudden headache without triggers or typical symptoms. Coronary computed tomography angiography (CTA) showed diffuse stenosis in the left anterior descending and the first diagonal branch arteries. His headache improved after percutaneous coronary intervention. Cardiac cephalalgia is usually marked by severe headaches, autonomic signs, and often affects the occipital region. Electrocardiogram (ECG) might not always show abnormalities, and chest pain is not always present. In such cases, elevated cardiac enzymes can be crucial for diagnosis.
CONCLUSION: When a headache is the sole symptom of an acute coronary event, consider moderate to severe intensity, older age at onset, occipital localization, and autonomic signs. ECG, cardiac enzymes, and coronary CTA are valuable for accurate diagnosis and treatment.
Sleep terrors, categorized under disorders of arousal, more prevalent in pediatric population, generally are self-limited but sometimes can persist or occur in adulthood. These are primed by factors enhancing homeostatic drive on backdrop of developmental predisposition and are precipitated by factors increasing sleep fragmentation resulting in dissociated state of sleep with some cerebral regions showing abnormal slow wave activity and others fast activity. This phenotypically evolves into abrupt partial arousal with individual arousing from N3 or N2 sleep with behaviors representing intense fear such as crying with autonomic hyperactivity. There is no recollection of the event, and lack of vivid dream mentation although fragmented imagery may be noted. Behavioral management is of prime importance including addressing precipitating factors, family reassurance, safety measures, and scheduled awakenings. Pharmacologic agents such as clonazepam and antidepressants are used infrequently in case of disruptive episodes.
BACKGROUND: Aggressive lipid-lowering therapy is important for secondary prevention of acute myocardial infarction (AMI). The recommended target for low-density lipoprotein cholesterol (LDL-C) of <70 mg/dL is often not achieved. To address this gap, we implemented a clinical pathway in all hospitals that perform percutaneous coronary interventions (PCI) with primary care physicians in Nagasaki and aimed to validate the effectiveness of this pathway in an acute setting.
METHODS AND RESULTS: This retrospective cohort study included medical records extracted from 8 hospitals in Nagasaki, Japan, where PCI was performed for patients with AMI. The index date was defined as the date of hospitalization for AMI between July 1, 2021, and February 28, 2023. The primary outcome was the rate of achieving LDL-C <70 mg/dL at discharge. The median baseline LDL-C level at admission was 121 mg/dL (n=226) in the pre-implementation group and 116 mg/dL (n=163) in the post-implementation group. In the post-implementation group, 131 patients were treated using the clinical pathway. The rate of achieving LDL-C <70 mg/dL at discharge increased significantly from 37.2% before implementation to 54.6% after implementation. Logistic regression analysis revealed a positive correlation between the implementation of the clinical pathway and achieving LDL-C <70 mg/dL.
CONCLUSIONS: Implementation of a region-wide clinical pathway for LDL-C management significantly improved the rate of intensive lipid-lowering therapy and the achievement of LDL-C targets.
An active coloring concentrate can be prepared from the juice of cranberries and blueberries by treating juice or homogenate with an appropriate binding matrix. Assorted ion exchange resins such as cholestyramine are effective binding matrices, but the currently preferred material is a food grade of cross-linked polyvinyl pyrollidone. The binding matrices are used to concentrate active materials from cranberry and a colored solid is produced. This substance shows anti-bacterial and anti-viral properties. It can be readily consumed as a therapeutic or nutraceutical, used as a coloring agent, or it can be used topically. Significant amounts of active concentrate can be produced from cranberry presscake which is normally a waste material.
PURPOSE:To enable the blocking of the generation of mildew for a lone time by repeating plural times a process of holding a hydraulic calcium phosphate cement curing liquid containing water soluble saccharides with a specified pH under a dry condition at a specified temperature for a specified period of time. CONSTITUTION:Phosphoric acid, citric acid, sodium carbonate, sodium hydroxide and the like are added to a hydraulic calcium phosphate cement curing liquid to control a pH value thereof to a range of 4.0-10.0. The hydraulic liquid with this range of pH is held under a dry condition to meet treating requirements of 50-90 deg. and 30-120min. Anti-milldew treatment is performed by repeating this holding process a plurality of times. In the heating treatment under the dry condition, it is preferable that the hydraulic liquid is preserved in a dry container set to 50-90 deg.C together with a heat resisting container or others. The heating holding treatment under the dry condition is repeated two to eight times preferably. A sample of the water soluble polysaccharides to be added to the hydraulic liquid is chitin, chitosan or soluble starch or the like.
BACKGROUND: Immediate prepectoral implant-based breast reconstruction (IBBR) rates have increased in recent years owing to improved cosmetic and psychological benefits. However, there is a lack of studies regarding complications rates following adjuvant radiotherapy (RT) among patients undergoing immediate prepectoral IBBR.
METHODS: We conducted a retrospective monocentric analysis of a cohort of consecutively treated patients who underwent NSM following immediate prepectoral IBBR at our institution between March 2017 and November 2021. Patient demographics, quality of life, complication rates, and oncological safety were evaluated in the RT and non-RT groups. Data analysis was performed using IBM SPSS Version 24 (IMB Corp., Armonk, NY, USA).
RESULTS: A total of 98 patients were examined: 70 were assigned to have prepectoral IBBR without RT and 28 to the group who had prepectoral IBBR with RT. There was a statistically significant difference in overall capsular contracture rate between the RT and non-RT group (18% vs. 4.3%, p=0.04). The total implant loss in the cohort was 4% (10.7% vs. 1.4%, p=0.05). We obtained a high percentages of all BREAST-Q categories in both groups; however, satisfaction with the breast and sexual well-being was higher in the non-RT group. The three-year overall survivals were 97.4% in the RT group and 98.5% in the non-RT group.
CONCLUSION: Our findings showed that patients in the RT group had a higher rate of capsular contracture and implant loss than those in the non-RT group. However, complication rates were within acceptable range and with accurate preoperative information patients have more benefits from immediate reconstruction showing excellent overall quality of life irrespectively of radiation.
LEVEL OF EVIDENCE III: This journal requires that authors assign a level of evidence to each article. For a full description of these Evidence-Based Medicine ratings, please refer to the Table of Contents or the online Instructions to Authors www.springer.com/00266 .
The second group was received conventional physiotherapy and, activity training which the same movement patterns with virtual reality games for 60 minutes. The children in the activity training group received unilateral, bilateral, and bimanual activity training that supported manual skills for thirty minutes. Similar activity patterns were presented to the virtual reality group and activity training (control) group. The treatment were given three times a week for eight weeks.
Local progression of primary skull base chordoma (PSBC) is a sign of treatment failure. Predicting the postoperative progression of PSBC can aid in the development of individualized treatment plans to improve patients' progression-free survival (PFS) after surgery. This study aimed to develop a multiparametric MRI-based fusion radiomic model (FRM) and clinicoradiomic model (CRM) via radiomic and clinical analysis and to explore their validity in predicting postoperative progression in PSBC patients before surgery. In this retrospective study, a total of 129 patients with PSBC from our institution, including 57 patients with progression, were enrolled and randomized to the training set (TS) or the validation set (VS) at a 2:1 ratio. Radiomic features were extracted and dimensionally reduced from 3.0 T/axial T2-weighted imaging (T2WI), T1-weighted imaging (T1WI) and contrast-enhanced T1-weighted imaging (CE-T1WI) sequences for each patient, and the features were used for radiomic analysis. Univariate and multivariate Cox regression analyses were used to screen for key clinical factors. We constructed models on the basis of multivariate logistic regression analysis. Receiver operating characteristic (ROC) curve, calibration curve, and decision curve analyses were performed to evaluate the performance of the clinical model (CM), FRM and CRM. Through analysis, we found that blood supply was the only significantly different clinical factor in the CM. For the FRM, the area under the receiver operating characteristic curve (AUC) of the TS was 0.925, and the calibration curves were consistent across the TS. In the CRM, the AUC of the TS was 0.929, the calibration curve analysis was consistent for both the TS and the VS, and the DCA showed that the net benefit was greater at a threshold probability of > 0% for both the TS and the VS. Our proposed FRM can help clinicians better predict PSBC progression preoperatively, and the use of the CRM can lead to the development of more appropriate protocols to improve patients' PFS after surgery.
The Detection of Early lung Cancer Among Military Personnel (DECAMP) consortium is a multidisciplinary and translational research program that includes 7 Veterans Administration Hospitals (VAH), the 4 designated Military Treatment Facilities (MTF) and 4 academic hospitals as clinical study sites, several molecular biomarker laboratories, along with Biostatics, Bioinformatics, Pathology and Biorepository cores. The DECAMP Coordinating Center will facilitate rapid selection, design and execution of clinical studies within this multi-institutional consortium. The goal will be accomplished by recruiting 500 smokers with indeterminate pulmonary nodules (0.7cm - 3.0cm) on chest CT who will undergo fiberoptic bronchoscopy and will be followed for 2 years until a final diagnosis is made. The diagnostic performance of four previously established lung cancer biomarkers in this cohort will be validated; 1) a gene-expression biomarker measured in bronchial airway brushings; 2) a proteomic signatures measured in bronchial airway biopsies; 3) a proteomic signature measured in serum; and 4) a signature of serum cytokines. The added value of the molecular markers to clinical and imaging markers routinely used in the diagnostic work up of these patients and develop an integrated model (i.e. clinical, imaging \& molecular markers) that results in the most robust diagnostic predictor will be evaluated.
A compressed detergent tablet adapted to disintegrate in aqueous fluids contains as an ingredient to accelerate said disintegration a cold water swelling and cold water dispersible ungelatinized starch derivative in its intact granule form. Ungelatinized cold water swelling cold water dispersible starch phosphate, sulphate or carboxymethyl starch ether are the preferred starch derivatives. They may be used in quantities of 1 to 50 and preferably 3 to 20% of the tablet composition.  An example is given of a tablet containing 65 parts of an alkyl aryl sulphonate, 15 parts of talc and 20 parts of corn starch phosphate.  Specification 713,750 is referred to.ALSO:A compressed laundry bleach tablet adapted to disintegrate in aqueous fluids contains as an ingredient to accelerate said disintegration a cold water swelling and cold water dispersible ungelatinized starch derivative in its intact granule form. Ungelatinized cold water swelling cold water dispersible starch phosphate, sulphate or carboxymethyl starch ether are the preferred starch derivatives.  They may be used in quantities of 1 to 50% of the tablet composition.  An example is given of a tablet containing sodium hexametaphosphate, sodium perborate, sodium sulphate, gum arabic and corn starch phosphate. Specification 713,750 is referred to.ALSO:Compressed tablets containing ingredients adapted to be disintegrated in aqueous fluids include as an ingredient to accelerate said disintegration a cold water swelling and cold water dispersible ungelatinized starch derivative in its intact granule form.  An ungelatinized cold water swelling cold water dispersible starch phosphate, sulphate or carboxymethyl starch ether are the preferred starch derivatives.  They may be used in quantities of 1 to 50 and preferably 3 to 20% of the tablet composition.  A tranquillizer tablet contains 2 - methyl - 2 - n - propyl - 1,3 - propanediol dicarbamate, methyl cellulose, magnesium stearate and the starch derivative.  Specification 713,750 is referred to.
Low back pain (LBP) is one of the most frequent ailments in industrialized countries, with a lifetime prevalence of more than 70%, and is responsible for a major portion of work absenteeism. Measuring disability is important in LBP. First, as an outcome measure, it is an important indicator of the quality of life of the patient. The Oswestry Disability Index (ODI) and the Roland Morris Disability Questionnaire (RMDQ) have emerged as the most commonly recommended condition specific outcome measures for spinal disorders.

The development of the ODI was initiated by John O'Brien in 1976. The index was designed as a measure for both assessment and outcome on patients with low back pain. The questionnaire can be completed in less than 5 minutes and scored in less than 1 minute. Version 1.0 of the questionnaire was published in 1980 and widely disseminated after the 1981 meeting of the International Society for The Study of the Lumbar Spine (ISSLS) in Paris. A new ODI version was adapted in 1989 by the Chiropractic College in England. The American Academy of Orthopedic Surgeons and other spine associations adapted the ODI 1.0 version in 1996 omitting categories 1, 8 and 9. This version is included in the assessment protocol proposed by the Musculoskeletal Outcomes Data Evaluation and Management System (MODEMS), which brings together the main international spine associations. Version 2.0 was modified by the Medical Research Council Group in the UK in 1996 (16) and they omitted the word "painkillers" in the first category. Version 2.1a is the most recent and recommended by its author. In this version a section called previous treatment appears, which is not taken into account for scoring. The score can be obtained for its clinical use after permission at: http://www.mapi-trust.org/.

The RMDQ is a health status measure designed to be completed by patients to assess physical disability due to low back pain. It was designed for use in research (e.g., as an outcome measure for clinical trials) but has also been found useful for monitoring patients in clinical practice. Was derived from the Sickness Impact Profile (SIP), which is a 136 item health status measure covering all aspects of physical and mental function. Twenty four items were selected from the SIP by the original authors. It is simple, fast, and can be filled out by the patient. The patient must mark each item that applies to his or her current LBP. Scoring is also simple and fast; each checked item receives a score of 1, so scores range between 0 (no disability caused by LBP) and 24 (the maximum possible disability). To date only one version has been translated to Spanish and was published in 2002 by Kovacks FM, et al.
PURPOSE:To obtain an inhibitor of melanogenesis, containing a specific triazole derivative having excellent inhibiting action on melanogenesis as an active ingredient and capable of safely and effectively treating pigmentation diseases such as exogenous or endogenous chloasma. CONSTITUTION:A medicine for external use capable of inhibiting melanogenesis is obtained by blending one or two or more selected from the group of compounds expressed by formula I (X is H, alkali metal, ammonium or organic amine residue; R<1> is H, alkyl, cyclohexyl, cyclopentyl, alkenyl, alkynyl, aralkyl, phenyl, heterocyclic ring, etc.; Z is H, alkyl, cyclohexyl, cyclopentyl, aralkyl, phenyl, heterocyclic ring, etc.) (e.g. a compound expressed by formula II, III, IV or V). The compounds expressed by formula I are odorless and excellent in stability due to no occurrence of discoloration by oxidation and precipitation with time. The compounds expressed by formula I are preferably blended in an amount of preferably 0.01-10wt.% based on the total amount of the medicine for external use.
Participants first received oral placebo. After at least 3 days wash-out participants get oral AV-101 720mg (matching placebo capsules). After at least 3 days wash-out participants get oral AV-101 1440mg (matching placebo capsules).
PURPOSE: A pharmaceutical composition for treating bacterial vaginitis is provided to suppress antibiotics resistant staphylococcus and to ensure strong epithelial cell adhesion ability. CONSTITUTION: A pharmaceutical composition for intravaginal administration for treating bacterial vaginitis contains Lactobacillus fermentum No. 1969 strain(KCTC 11437BP) as an active ingredient. The Lactobacillus fermentum No. 1969 strain has abilities of generating hydrogen peroxide and adhering to vaginal epithelial cells. The Lactobacillus fermentum No. 1969 strain suppresses to staphylococcus. The Lactobacillus fermentum No. 1969 strain is contained in a freeze-dried powder form.
An alkoxyphenylalkylamine derivative represented by general formula (I) and a salt thereof, wherein X?1 and X2¿ may be the same or different from each other and each represents hydrogen, halogen, hydroxyl, or C¿1? to C5 alkoxy which may be substituted by phenyl; R?1 and R2¿ may be the same or different from each other and each represents hydrogen or C¿1? to C7 alkyl which may be terminated with hydroxyl, carboxyl or alkoxycarbonyl, or alternatively R?1 and R2¿ are combined with the adjacent nitrogen atoms to represent optionally substituted pyrrolidine, piperidino, piperazino, etc.; A represents phenyl which may be substituted by one to three arbitrary substituents selected among halogen, hydroxyl and C¿1? to C5 alkoxy, or similarly substituted thienyl; m represents an integer of 2 to 5; and n represents an integer of 1 to 7. The above compounds are useful in treating schizophrenia without causing extrapyramidal disorder and in treating problematic behaviours accompanying cerebrovascular disorder or senile dementia.
FIELD: medicine, pharmaceutics.SUBSTANCE: invention refers to the pharmaceutical industry, namely to an agent with an antidyslipidemic and analgesic effect. The method for preparing the phytocomplex with the antidyslipidemic and analgesic effect, involving: a) grinding peeled bergamot fruit to prepare an undegraded mixture, b) introducing pectinolytic enzymes into the mixture; c) reducing pulp content; d) inactivating the above enzymes added at the stage b), to prepare a degraded mixture; e) performing ultrafiltration of the degraded mixture through membranes isolating the substances having a molecular weight of over 30,000 Da, to prepare a transparent solution; f) introducing the transparent solution on a polyphenol absorption column; g) washing the polyphenol absorption column with water and increasing pH to prepare an aqueous polyphenol fraction; h) transmitting the aqueous polyphenol fraction to cationic resin to recover the phytocomplex in an aqueous phase; i) drying the phytocomplex in the aqueous phase. The phytocomplex in the aqueous phase with the antidyslipidemic and analgesic effect. The phytocomplex with the antidyslipidemic and analgesic effect. A pharmaceutical composition with the antidyslipidemic effect containing the phytocomplex, and pharmaceutically acceptable additives. A pharmaceutical composition with the analgesic effect containing the phytocomplex, and pharmaceutically acceptable additives.EFFECT: phytocomplex described above possesses the evident antidyslipidemic and analgesic effect.11 cl